i-Cognitio Sciences

What i-Cognitio Sciences does

i-Cognitio Sciences is a Hong Kong-based medical technology company that develops AI-powered retinal imaging analysis software for early detection of Alzheimer's disease and cognitive decline. The company's core product, RetinAD 1.0, applies machine learning models trained on a proprietary multi-ethnic dataset of over 16,000 retinal images to triage individuals at risk for Alzheimer's dementia and to flag those with suboptimal control of modifiable risk factors such as hypertension and diabetes. The platform is delivered as a cloud-based SaaS solution with disclosed performance of 90% specificity and 94% sensitivity in distinguishing Alzheimer's dementia from cognitively normal subjects, validated through internal and external tests.

The company was founded by three professors from The Chinese University of Hong Kong (CUHK) — Vincent Mok (neurology), Carol Cheung (ocular imaging), and Owen Ko (AI/medical technology) — and is privately held with no disclosed funding rounds. RetinAD 1.0 is deployed through B2B enterprise sales and OEM-embedded channels, including alliances with retinal camera manufacturers for hardware-level integration and a partnership with Humansa to distribute screening to AIA Hong Kong's Alta Club membership programme for high-net-worth customers.

Revenue mechanics center on SaaS platform licensing (subscription/recurring) and B2B enterprise licensing to healthcare providers, clinics, hospitals, optical shops, body-check centers, and longevity programme providers. Pricing is quote-based and not publicly disclosed. The company targets two primary segments — healthcare providers (vertical) and insurers/longevity service providers — with a secondary segment of health-conscious individuals for primary prevention. Future plans include mobile app integration and product expansion into diabetic retinal disease, glaucoma, and broader dementia diagnosis.

Name

i-Cognitio Sciences

Legal name

i-Cognitio Sciences

Website

https://i-cognitio.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

i-Cognitio Sciences is a Hong Kong-based medical AI company that provides RetinAD 1.0, a cloud-based SaaS platform using retinal imaging and machine learning to triage Alzheimer's and cognitive decline risk for healthcare providers, insurers, and longevity programmes.

Ownership category

akta.pro rank

Product category

AI Healthcare Diagnostics

NAICS

Software Publishers (5132), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)

SIC

Laboratory Analytical Instruments (3826), Services-Computer Integrated Systems Design (7373)

akta.pro primary industry

Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography) (HLAHAJAB)

Keywords

• AI healthcare diagnostics
• Retinal imaging analysis
• Brain health assessment
• Alzheimer's screening software
• Medical imaging SaaS

Headquarters

HQ city

Tuen Mun

HQ country

Hong Kong SAR China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. SaaS Platform Licensing: Cloud-based SaaS subscription model providing brain health assessment services to healthcare providers, clinics, hospitals, and other medical organizations. Scalable per-assessment or subscription-based pricing for B2B customers.
2. B2B Enterprise Licensing: Licensing of RetinAD platform to strategic partners including retinal camera manufacturers and healthcare organizations for integration into their medical settings and screening initiatives.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Core offering

i-Cognitio Sciences develops and sells RetinAD 1.0, a cloud-based AI software platform that analyzes retinal images to triage individuals at risk of Alzheimer's dementia and identify suboptimal control of modifiable risk factors. The platform is offered as a SaaS subscription and through enterprise licensing to healthcare providers, clinics, hospitals, optical shops, longevity programmes, and insurance partners.

Product overview

i-Cognitio Sciences offers a single core product called RetinAD 1.0, an AI-powered non-invasive brain health assessment platform. The platform leverages retinal imaging analysis combined with machine learning algorithms to detect early signs of Alzheimer's dementia and cognitive decline. The technology provides a triage mechanism to identify individuals who may benefit from further in-depth evaluations, and is offered as a cloud-based SaaS solution with future plans to expand into diabetic retinal disease, glaucoma, and broader dementia diagnosis.

Differentiator

Problem solved

Functional benefit

Brands

• RetinAD 1.0: AI-powered non-invasive assessment of brain health and Alzheimer's risk using retinal imaging analysis. Achieves 94% sensitivity and 90% specificity in distinguishing Alzheimer's dementia from cognitive normal subjects.

Products and services

• RetinAD 1.0 AI-powered non-invasive brain health assessment platform that analyzes retinal images to triage individuals at risk for Alzheimer's dementia and identify cognitively normal individuals with suboptimal control of modifiable risk factors such as hypertension, diabetes, and lifestyle habits. Designed for healthcare providers, clinics, hospitals, optical shops, body-check centers, longevity programmes, and insurance partners.

Quantifiable outcome

• 90% specificity and 94% sensitivity in distinguishing Alzheimer's dementia from cognitive normal subjects
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Partnerships

Four partnerships are on record, tiered core.

• HumansacoreChannel Partner/ Reseller/ Distributor · 2 March 2026Strategic collaboration with Humansa for deployment of AI-powered retinal imaging brain health screening solution. Humansa serves as healthcare service provider enabling distribution to AIA Hong Kong's Alta Club membership programme, reaching high-net-worth customers seeking cognitive health assessment.
• Sengital LimitedcoreStrategic or Co-development PartnerStrategic partnership with industry leader Sengital Limited to develop and bring innovative AI-driven ocular imaging solutions to the forefront of medical diagnostics. Collaboration empowers the company to integrate advanced technology into commercial products.
• Major Retinal Camera ManufacturerscoreTechnology or IntegrationStrategic alliances with leading retinal camera manufacturers to integrate RetinAD platform with cutting-edge ocular imaging hardware. These partnerships ensure widespread deployment and usability of the AI-powered brain health assessment tool across diverse medical settings globally.
• Healthcare OrganizationscoreChannel Partner/ Reseller/ DistributorStrategic alliances with healthcare organizations for enhanced reach and impact. RetinAD is integrated into diverse medical settings from local clinics and specialized centers to global screening initiatives, maximizing the tool's impact on global health through primary prevention.

Scale indicators5 records

Recent moves5 records

Expansion highlights3 records

Direct peers

• Altoida: Altoida uses AI-driven digital biomarkers (including cognitive and functional assessments) for early detection of Alzheimer's disease, competing in the same neurodegeneration risk-assessment space.
• BrainCheck: BrainCheck delivers cognitive assessment software for clinicians to detect and manage cognitive impairment and dementia, serving a similar provider customer base as i-Cognitio.
• Neurotrack Technologies: Neurotrack develops digital cognitive health assessments for early detection of Alzheimer's and cognitive decline, targeting similar enterprise healthcare and consumer wellness use cases as i-Cognitio.
• Cogstate: Cogstate provides computerised cognitive testing and brain health assessment tools used by clinicians, researchers, and pharmaceutical trials, overlapping with i-Cognitio's cognitive screening and risk-stratification positioning.
• RetiSpec: RetiSpec is a direct competitor using AI-driven retinal imaging to detect Alzheimer's disease and other neurodegenerative conditions, making it the closest functional and technical peer to i-Cognitio's RetinAD platform.
• Cambridge Cognition: Cambridge Cognition offers digital cognitive assessment platforms for clinical trials, healthcare, and research, addressing the same neurodegenerative disease screening market as RetinAD.

Others

• AIA Hong Kong: AIA Hong Kong is i-Cognitio's anchor enterprise customer and distribution partner through the Alta Club programme, illustrating the insurer-led channel model i-Cognitio aims to replicate with other payers.
• Sengital Limited: Sengital is both a strategic partner and an adjacent ocular imaging hardware/commercial player; its broader ocular imaging solutions portfolio overlaps with the retinal imaging infrastructure that RetinAD depends on.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/i-cognitio-sciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about i-Cognitio Sciences